Scott Lesley J
Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand.
Clin Drug Investig. 2015 Nov;35(11):765-72. doi: 10.1007/s40261-015-0348-9.
Oral teneligliptin [Teneglucon® (Argentina)], a dipeptidyl peptidase-4 inhibitor, is indicated for the treatment of adults with type 2 diabetes (T2DM). This article reviews the pharmacology, therapeutic efficacy and tolerability of teneligliptin in the treatment of adults with T2DM. In 12- or 16-week, placebo-controlled phase 2 and 3 trials, oral teneligliptin 20 or 40 mg once daily, as monotherapy or in combination with metformin, glimepiride or pioglitazone improved glycaemic control, including in patients with end-stage renal disease, and was generally well tolerated. Most treatment-emergent adverse events were of mild intensity and relatively few patients discontinued treatment because of these events. Improvements in glycaemic control observed in short-term trials were maintained at 52 weeks in extension phases of these trials and in 52-week interventional studies, with no new safety concerns identified during this period. In the absence of direct head-to-head clinical trials, the position of teneligliptin relative to other antidiabetic agents in the management of T2DM remains to be determined. In the meantime, teneligliptin is a useful treatment option for adults with T2DM who have not responded adequately to diet and exercise regimens, or the addition of antidiabetic drugs.
口服替格列汀[Teneglucon®（阿根廷）]，一种二肽基肽酶-4抑制剂，适用于治疗成年2型糖尿病（T2DM）患者。本文综述了替格列汀治疗成年T2DM患者的药理学、治疗效果和耐受性。在为期12周或16周的安慰剂对照2期和3期试验中，口服替格列汀20或40mg每日一次，作为单一疗法或与二甲双胍、格列美脲或吡格列酮联合使用，均可改善血糖控制，包括终末期肾病患者，且总体耐受性良好。大多数治疗中出现的不良事件强度较轻，因这些事件而停药的患者相对较少。在这些试验的延长期以及52周的干预性研究中，短期试验中观察到的血糖控制改善情况在52周时得以维持，在此期间未发现新的安全问题。由于缺乏直接的头对头临床试验，替格列汀在T2DM管理中相对于其他抗糖尿病药物的地位仍有待确定。与此同时，对于饮食和运动方案或加用抗糖尿病药物反应不佳的成年T2DM患者，替格列汀是一种有用的治疗选择。
